The 503B Deadline Holds: Court Declines to Shield Large-Scale GLP-1 Compounding (March 2025)

March 19, 2025 was the date large-scale compounded tirzepatide was supposed to end — the FDA's enforcement deadline for 503B outsourcing facilities after the shortage resolution — and despite the Outsourcing Facilities Association's litigation, it substantially did.

The OFA had sued to overturn the FDA's October 2024 shortage-resolution determination (reaffirmed that December), arguing supply remained inadequate. Courts declined to block enforcement while the case proceeded, the deadlines held, and the industrial base of the compounded boom — FDA-registered facilities producing batches without patient-specific prescriptions — wound down GLP-1 lines or moved to contested workarounds.

What survived was the 503A lane: patient-specific prescriptions from state-licensed pharmacies, the legal theory under which nearly every program in our database operates today. The structural consequence shows up in our data as the pharmacy-disclosure problem — thousands of state-regulated pharmacies of highly variable quality replaced a smaller set of federally inspected facilities, which is why "which pharmacy, by name?" became the single most important diligence question, and why the two programs that answer it unprompted (NexLife's named 503A/503B network; Mochi's owned facility) earn transparency points no price can buy.